Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Completed · Phase 2 · Has a placebo group

Conditions studied: Muscle Wasting (Atrophy) After Hip Fracture Surgery

In brief

The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.

Key facts

Study ID

NCT02152761

Run by

Novartis Pharmaceuticals

People needed

251

Starts

2014-09-16

Expected to finish

2018-10-25

Last updated by the study team

2020-08-19

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have X-ray confirmed successful hip fracture repair; Must have completed surgical wound healing; Ability to walk a specified distance with or without a walking aid; Must weigh at least 35 kg.

You may not qualify if…

• Must not have history of any other lower limb fractures in the past 6 months; Must not have certain cardiovascular conditions; Must not have a chronic active infection (e.g. HIV, hepatitis B or C, etc); Must not have used high-dose corticosteroid medications for at least 3 months in the past year;

Where it is running

• Novartis Investigative Site — El Cajon, California, United States
• Novartis Investigative Site — Denver, Colorado, United States
• Novartis Investigative Site — Gainesville, Georgia, United States
• Novartis Investigative Site — Rochester, Minnesota, United States
• Novartis Investigative Site — New York, New York, United States
• Novartis Investigative Site — Ciudad Autonoma de Bs As, Argentina
• Novartis Investigative Site — Bedford Park, South Australia, Australia
• Novartis Investigative Site — Graz, Austria
• Novartis Investigative Site — Bruges, Belgium
• Novartis Investigative Site — Genk, Belgium
• Novartis Investigative Site — Ghent, Belgium
• Novartis Investigative Site — Santiago, Chile
• Novartis Investigative Site — Cali, Valle del Cauca Department, Colombia
• Novartis Investigative Site — Barranquilla, Colombia
• Novartis Investigative Site — Brno, Czech Republic, Czechia
• Novartis Investigative Site — Hradec Králové, Czech Republic, Czechia
• Novartis Investigative Site — Pardubice, Czech Republic, Czechia
• Novartis Investigative Site — Pilsen, Czech Republic, Czechia
• Novartis Investigative Site — Prague, Czech Republic, Czechia
• Novartis Investigative Site — Prague, Czechia
• Novartis Investigative Site — Lille, France
• Novartis Investigative Site — Montpellier, France
• Novartis Investigative Site — Bad Abbach, Germany
• Novartis Investigative Site — Dresden, Germany
• Novartis Investigative Site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.